Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.

Urologic oncology - 1 Jan 2014

Sung Ji-Youn, Sun Jong-Mu, Chang Jeong Byong, Il Seo Seong, Soo Jeon Seong, Moo Lee Hyun, Yong Choi Han, Young Kang So, Choi Yoon-La, Young Kwon Ghee

Abstract excerpt

BACKGROUND: Alterations in fibroblast growth factor receptor 3 (FGFR3) have been implicated in the pathogenesis of urothelial carcinoma. However, its clinicopathological significance has not been clearly established, especially in muscle-invasive bladder cancer (MIBC). OBJECTIVES: The aim of our study was to investigate the mutation and overexpression of FGFR3 in MIBC cases from radical cystectomy and to analyze...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chemotherapy, Adjuvant
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscles

Share to Neoplasm Invasiveness

Share to Outcome Assessment, Health Care

Share to Proportional Hazards Models

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 24360661
DOI: 10.1016/j.urolonc.2013.07.015

Genes

FGFR3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.PMID 24360661Read ↗

FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†.Semantic proximity Read ↗

Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.Semantic proximity Read ↗

The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer.Semantic proximity Read ↗

Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-Invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.Semantic proximity Read ↗

FGFR3 – a Central Player in Bladder Cancer Pathogenesis?Semantic proximity Read ↗

FGFR3 mutational status and protein expression in patients with bladder cancer in a Jordanian population.Semantic proximity Read ↗

Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.Semantic proximity Read ↗

Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.Semantic proximity Read ↗

A place for precision medicine in bladder cancer: targeting the FGFRs.Semantic proximity Read ↗

Fibroblast growth factor receptor 3 (FGFR3) aberrations in muscle-invasive urothelial carcinoma.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.